Gastric Cancer Clinical Trials

Scottsdale : Site Reference ID/Investigator# 24987

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Beverly HIlls : Research Center

A clinical research study for patients with gastric cancer.

Beverly HIlls : Research Site

A clinical research study for patients with gastric cancer.

View More »

Bakersfield : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Duarte : City of Hope Cancer Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

La Jolla : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Los Angeles : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Los Angeles : Site Reference ID/Investigator# 24985

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Stanford : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Whittier : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Denver : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

New Haven :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

New Haven : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Washington : Site Reference ID/Investigator# 24986

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Jacksonville : Mayo Clinic

Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia

Pembroke Pines : Memorial Cancer Institute

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

St Petersburg :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Savannah : Memorial University Medical Center

SWOG S1005: A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer.

View More »

Atlanta : Piedmont Hospital Research Institute

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Elgin : Sherman Health

SWOG S1201 Phase II Randomized, Pilot Study of FOLFOX Therapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Versus Irinotecan Hydrochloride and Docetaxel in Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

View More »

Chicago :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Chicago : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Niles :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Goshen : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Alexandria : Research Site

A clinical research study for patients with gastric cancer.

Boston : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Boston : Dana-Farber Cancer Institute

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Boston : Massachusetts General Hospital

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Woodbury : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Omaha : Nebraska Cancer Specialists, Methodist Estabrook Cancer Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Henderson : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Basking Ridge : Memoral Sloan Kettering Cancer Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Albuquerque : Research Site

A clinical research study for patients with gastric cancer.

Albuquerque : Research Center

A clinical research study for patients with gastric cancer.

Albany :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Jamaica : Queens Cancer Center of Queens Hospital

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

New Hyde Park : Long Island Jewish Medical Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

New York : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

View More »

New York : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

New York : Memorial Sloan-Kettering Cancer Center

Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

New York : Memorial Sloan-Kettering Cancer Center

Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers

New York : Memorial Sloan-Kettering Cancer Center 1275 York Avenue

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

New York : Weill Medical College of Cornell University

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Sleepy Hollow : Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Durham : Site Reference ID/Investigator# 24922

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Greensboro : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Winston Salem : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Cincinnati :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Hershey : Research Center

A clinical research study for patients with gastric cancer.

View More »

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Pittsburgh : University of Pittsburgh Cancer Institute

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Rockledge : Fox Chase Cancer Center

An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

Charleston : Research Center

A clinical research study for patients with gastric cancer.

Charleston : Research Site

A clinical research study for patients with gastric cancer.

View More »

Charleston : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Nashville :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Nashville : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Nashville : Site Reference ID/Investigator# 24983

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Nashville : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

View More »

Nashville : Sarah Cannon Research Institute

Safety Study of MGAH22 in HER2-positive Carcinomas

Dallas : Research Center

A clinical research study for patients with gastric cancer.

Houston : Research Site

A clinical research study for patients with gastric cancer.

View More »

Austin :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Bedford : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Dallas : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Garland :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Houston : UT MD Anderson Cancer Center

Chemoradiation-Induced Nausea and Emesis: Quality of Life

San Antonio : The University of Texas Health Science Center-CTRC

An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

Fairfax :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Richmond :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Vancouver :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Milwaukee : Medical College of Wisconsin

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Rosario : Research Site

A clinical research study for patients with gastric cancer.

Douglas : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

East Bentleigh :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Elizabeth Vale : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Heidelberg :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Heidelberg : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

View More »

Herston :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Kurralta Park : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Nedlands :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Port Macquarie : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Randwick : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Sydney :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Wahroonga : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Woodville South : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Woodville South :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Bruxelles : Research Center

A clinical research study for patients with gastric cancer.

Edegem : Research Site

A clinical research study for patients with gastric cancer.

Gent : Research Center

A clinical research study for patients with gastric cancer.

Liège : Research Site

A clinical research study for patients with gastric cancer.

View More »

Brugge : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Brussels (anderlecht) : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Brussels (woluwe-st-lambert) : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Leuven : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Leuven : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Leuven : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Liege : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Sint-niklaas : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Barretos : Research Site

A clinical research study for patients with gastric cancer.

Belo Horizonte : Research Site

A clinical research study for patients with gastric cancer.

Fortaleza : Research Site

A clinical research study for patients with gastric cancer.

Ijuí : Research Site

A clinical research study for patients with gastric cancer.

Porto Alegre : Research Site

A clinical research study for patients with gastric cancer.

Ribeirão Preto : Research Site

A clinical research study for patients with gastric cancer.

Salvador : Research Site

A clinical research study for patients with gastric cancer.

São Paulo : Research Site

A clinical research study for patients with gastric cancer.

São Paulo : Research Site

A clinical research study for patients with gastric cancer.

View More »

Barretos : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Porto Alegre : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Rio de Janeiro : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Sao Paulo : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Sorocaba : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Gabrovo : Research Center

A clinical research study for patients with gastric cancer.

Pleven : Research Site

A clinical research study for patients with gastric cancer.

Varna : Research Center

A clinical research study for patients with gastric cancer.

Vratsa : Research Center

A clinical research study for patients with gastric cancer.

View More »

Sofia : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Brampton : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Fredericton : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Laval : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Toronto : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Vancouver : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Santiago : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Viña Del Mar : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Beijing : Beijing Cancer Hospital

A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery

Beijing : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Beijing : Beijing Cancer Hospital

Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

Chang Sha : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Changchun : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

View More »

Guangzhou : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Shanghai : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Wuhan : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Teusaquillo : Research Center

A clinical research study for patients with gastric cancer.

Osijek : Research Center

A clinical research study for patients with gastric cancer.

Zagreb : Research Site

A clinical research study for patients with gastric cancer.

Brno : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Hradec Kralove : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Olomouc : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Olomouc : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Praha : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

View More »

Praha 2 : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Praha 2 : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Praha 8 : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Tallinn : Research Site

A clinical research study for patients with gastric cancer.

Tallinn : Research Site

A clinical research study for patients with gastric cancer.

Tampere : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Angers : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Avignon : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Besancon : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Brest Cedex : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Clichy : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

View More »

Paris : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Saint Herblain : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Toulouse : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Villejuif : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Aachen : Research Center

A clinical research study for patients with gastric cancer.

Essen : Research Site

A clinical research study for patients with gastric cancer.

Herne, NRW : Research Site

A clinical research study for patients with gastric cancer.

Leverkusen : Research Center

A clinical research study for patients with gastric cancer.

Muenchen : Research Center

A clinical research study for patients with gastric cancer.

Trier, RP : Research Site

A clinical research study for patients with gastric cancer.

View More »

Berlin : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Berlin : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Frankfurt :

An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

Hamburg : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Landshut : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Magedburg : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Mainz : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Mannheim : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Athens : 2nd Dept of Medical Oncology, Metropolitan Hospital

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Athens : 3rd Dept of Medical Oncology, Hygeia Hospital

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Athens : Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra"

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Athens : 1st Dept of Medical Oncology, Metropolitan Hospital

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Athens : 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

View More »

Athens : Division of Oncology, 2nd Dept of Internal Medicine, University Hospital "Attikon"

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Heraklio : Dept of Medical Oncology, University Hospital of Heraklion

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Ioannina : Dept of Medical Oncology, Ioannina University Hospital

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Patras : Division of Oncology, Dept of Internal Medicine, University Hospital of Patras

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Thessaloniki : Dept of Medical Oncology, Papageorgiou General Hospital

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer

Hong Kong : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Budapest : Research Center

A clinical research study for patients with gastric cancer.

Gyor : Research Center

A clinical research study for patients with gastric cancer.

Nyíregyháza : Research Site

A clinical research study for patients with gastric cancer.

Pécs : Research Center

A clinical research study for patients with gastric cancer.

Szeged : Research Center

A clinical research study for patients with gastric cancer.

Székesfehérvár : Research Center

A clinical research study for patients with gastric cancer.

View More »

Budapest : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Budapest : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Pecs : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Szeged : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Szolnok : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Szombathely : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Veszprem : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Zalaegerszeg : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Bangalore :

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Bangalore : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Chennai : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Hyderabad : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Nagpur :

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

View More »

Nagpur : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

New Delhi :

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Pune : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Vellore : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Vishakpatnam :

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Beer Sheva : Research Site

A clinical research study for patients with gastric cancer.

Jerusalem : Research Center

A clinical research study for patients with gastric cancer.

Kfar Saba : Research Center

A clinical research study for patients with gastric cancer.

Ramat Gan : Research Center

A clinical research study for patients with gastric cancer.

Tel Aviv : Research Center

A clinical research study for patients with gastric cancer.

Milano : Research Site

A clinical research study for patients with gastric cancer.

Milano : Research Center

A clinical research study for patients with gastric cancer.

Modena : Research Center

A clinical research study for patients with gastric cancer.

Potenza : Research Site

A clinical research study for patients with gastric cancer.

Reggio Emilia : Research Site

A clinical research study for patients with gastric cancer.

Rimini : Research Center

A clinical research study for patients with gastric cancer.

View More »

Ancona : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Ancona : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Bologna : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Catanzaro : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Catanzaro : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Catanzaro : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Firenze : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Firenze : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Florence : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Milano : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Milano : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Milano : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Pisa : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Pisa : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Pisa : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Pisa : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Prato : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Reggio Emilia : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Roma : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Roma : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Torino : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Udine : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Udine : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Aichi : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Chiba : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Kashiwa : Updated

A Phase I Study of E7050 in Subjects With Solid Tumors

Nagoya : Updated

A Phase I Study of E7050 in Subjects With Solid Tumors

Sapporo-shi : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Shizuoka : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Sunto : Updated

A Phase I Study of E7050 in Subjects With Solid Tumors

Takatsuki-shi : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Tokyo : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Anyang-si : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Bundang City : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Daegu : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Incheon : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Jeollanam-do : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

View More »

Jeonju-si : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Seongnam : Seoul National University Bundang Hospital

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Seongnam-si : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Seoul : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Seoul : Seoul National University Hospital

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Seoul : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Seoul :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Seoul : Investigational Site Number 410001

Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

Seoul : Administrative Office

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Seoul : Asan Medical Center

Dovitinib for Gastric Cancer With FGFR2 Amplification

Seoul : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Seoul : Seoul National University Hospital

Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

Seoul : Yonsei University Gangnam Severance Hospital

Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

Seoul : Seoul National University Hospital

Safety Study of MGAH22 in HER2-positive Carcinomas

Kuala Lumpur : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Sabah : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Chihuahua : Research Center

A clinical research study for patients with gastric cancer.

Mexico City : Research Site

A clinical research study for patients with gastric cancer.

View More »

Distrito Federal : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Mexico City : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Monterrey : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Oaxaca : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Amsterdam : Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis

Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)

Auckland : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Panama : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Arequipa : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Lima : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Trujillo : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Cebu : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Manila : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Pasig City : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Quezon City, Luzon : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Gdansk : Research Site

A clinical research study for patients with gastric cancer.

Lodz : Research Site

A clinical research study for patients with gastric cancer.

Olsztyn : Research Site

A clinical research study for patients with gastric cancer.

Szczecin : Research Site

A clinical research study for patients with gastric cancer.

Warszawa : Research Site

A clinical research study for patients with gastric cancer.

View More »

Gdansk : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Krakow : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Krakow : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Poznan : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Warsaw : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Aveiro : Research Center

A clinical research study for patients with gastric cancer.

Barreiro : Research Site

A clinical research study for patients with gastric cancer.

Coimbra : Research Center

A clinical research study for patients with gastric cancer.

Lisboa : Research Site

A clinical research study for patients with gastric cancer.

Porto : Research Site

A clinical research study for patients with gastric cancer.

View More »

Porto : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Baia Mare : Research Center

A clinical research study for patients with gastric cancer.

Cluj-Napoca : Research Site

A clinical research study for patients with gastric cancer.

Iasi : Research Center

A clinical research study for patients with gastric cancer.

Onesti : Research Center

A clinical research study for patients with gastric cancer.

View More »

Bucharest : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Cluj-napoca : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Barnaul : Research Center

A clinical research study for patients with gastric cancer.

Moscow : Research Site

A clinical research study for patients with gastric cancer.

Saint Petersburg : Research Center

A clinical research study for patients with gastric cancer.

Saint Petersburg : Research Site

A clinical research study for patients with gastric cancer.

Saint-Petersburg : Research Site

A clinical research study for patients with gastric cancer.

Arkhangelsk : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Ivanovo : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Pyatigorsk : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Ryazan : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

St Petersburg : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

View More »

Stavropol : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Tula : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Tula : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Belgrade : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

NIS : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Sremska Kamenica : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Singapore :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Cape Town : Research Site

A clinical research study for patients with gastric cancer.

Cape Town : Research Site

A clinical research study for patients with gastric cancer.

Durban : Research Center

A clinical research study for patients with gastric cancer.

Groenkloof Pretoria : Research Center

A clinical research study for patients with gastric cancer.

Port Elisabeth : Research Site

A clinical research study for patients with gastric cancer.

Pretoria : Research Center

A clinical research study for patients with gastric cancer.

View More »

Johannesburg : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Barcelona : Research Site

A clinical research study for patients with gastric cancer.

Barcelona : Research Site

A clinical research study for patients with gastric cancer.

Barcelona : Research Site

A clinical research study for patients with gastric cancer.

Barcelona : Research Center

A clinical research study for patients with gastric cancer.

Barcelona : Research Center

A clinical research study for patients with gastric cancer.

Elche : Research Center

A clinical research study for patients with gastric cancer.

Madrid : Research Center

A clinical research study for patients with gastric cancer.

Madrid : Research Site

A clinical research study for patients with gastric cancer.

Madrid : Research Center

A clinical research study for patients with gastric cancer.

Madrid : Research Center

A clinical research study for patients with gastric cancer.

Madrid : Research Center

A clinical research study for patients with gastric cancer.

Malaga : Research Site

A clinical research study for patients with gastric cancer.

Sabadell : Research Center

A clinical research study for patients with gastric cancer.

Valencia : Research Center

A clinical research study for patients with gastric cancer.

View More »

A Coruna : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Barcelona : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Barcelona : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Barcelona : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Barcelona : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Elche : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Madrid : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Madrid : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Madrid : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Madrid : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Oviedo : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Oviedo : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Santander : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Santander : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Santander : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Santiago de Compostela : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Sevilla : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Sevilla : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Valencia : Updated

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

Zaragoza : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Zaragoza : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Bern : Research Site

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Luzern : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Zürich : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Kueishan :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Tainan :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Taipei :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Taipei : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Bangkok : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Bangkok :

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer

Chiang Rai : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Hat Yai : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Lopburi : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Adana : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Ankara :

A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)

Gaziantep :

A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)

Istanbul :

A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)

Istanbul : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

View More »

Izmir : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Izmir : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Konya :

A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)

Shhiye, Ankara : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Shhiye, Ankara :

A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)

Shhiye, Ankara : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Cherkassy : Research Center

A clinical research study for patients with gastric cancer.

Chernivtsiy : Research Center

A clinical research study for patients with gastric cancer.

Dnepropetrovsk : Research Center

A clinical research study for patients with gastric cancer.

Donetsk : Research Center

A clinical research study for patients with gastric cancer.

Kharkiv : Research Center

A clinical research study for patients with gastric cancer.

Kyiv : Research Site

A clinical research study for patients with gastric cancer.

Lutsk : Research Center

A clinical research study for patients with gastric cancer.

Lviv : Research Center

A clinical research study for patients with gastric cancer.

Sumy : Research Center

A clinical research study for patients with gastric cancer.

Uzhgorod : Research Center

A clinical research study for patients with gastric cancer.

Zaporizzhya : Research Center

A clinical research study for patients with gastric cancer.

View More »

Cherkassy : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

London : Research Center

A clinical research study for patients with gastric cancer.

Rhyl : Research Center

A clinical research study for patients with gastric cancer.

View More »

Aberdeen : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Bristol : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Cardiff : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Denbighshire : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Glasgow : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Leicester : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

London : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

London : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

London : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

London and Surrey : Royal Marsden NHS Foundation Trust

Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

Maidstone : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Manchester : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Manchester : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Manchester : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Southampton : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Southampton : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Sutton : Updated

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Sutton : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Sutton : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients

Weston Super Mare : Updated

A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer

Wolverhampton : Updated

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Wolverhampton : Research Site

Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients